Igor Bilinsky - Net Worth and Insider Trading

Igor Bilinsky Net Worth

The estimated net worth of Igor Bilinsky is at least $58 dollars as of 2026-09-06. Igor Bilinsky is the Sr VP, Corporate Development of Fresh Tracks Therapeutics Inc and owns about 62 shares of Fresh Tracks Therapeutics Inc (FRTX) stock worth over $58. Details can be seen in Igor Bilinsky's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Igor Bilinsky has not made any transactions after 2015-07-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Igor Bilinsky

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

FRTX Fresh Tracks Therapeutics Inc

100% of holdings · $58

Igor Bilinsky Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Igor Bilinsky owns 5 companies in total, including Oncternal Therapeutics Inc (ONCT) , Armata Pharmaceuticals Inc (ARMP) , and Ignyta Inc (RXDX) among others .

Click here to see the complete history of Igor Bilinsky’s form 4 insider trades.

Insider Ownership Summary of Igor Bilinsky

Ticker	Company	Transaction Date	Type of Owner
ONCT	Oncternal Therapeutics Inc	2019-09-09	Chief Business Officer
ARMP	Armata Pharmaceuticals Inc	2017-01-30	Chief Operating Officer
RXDX	Ignyta Inc	2016-01-07	GM & Immuno-Oncology/SVP Sp Ops
		2015-07-13	Senior VP & Corporate Dev't
		2021-03-15	Chief Operating Officer

Igor Bilinsky Latest Holdings Summary

Igor Bilinsky currently owns a total of 1 stock. Igor Bilinsky owns 62 shares of Fresh Tracks Therapeutics Inc (FRTX) as of July 13, 2015, with a value of $58.

Latest Holdings of Igor Bilinsky

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
FRTX	Fresh Tracks Therapeutics Inc	2015-07-13	62	0.94	58

Holding Weightings of Igor Bilinsky

Igor Bilinsky Form 4 Trading Tracker

According to the SEC Form 4 filings, Igor Bilinsky has made a total of 0 transactions in Fresh Tracks Therapeutics Inc (FRTX) over the past 5 years. The most-recent trade in Fresh Tracks Therapeutics Inc is the sale of 0 shares on July 13, 2015, which brought Igor Bilinsky around $881.

Insider Trading History of Igor Bilinsky

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Igor Bilinsky Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Igor Bilinsky owns.

- FRTX

View FRTX Analysis

Igor Bilinsky Ownership Network

Ownership Network List of Igor Bilinsky

No Data

Ownership Network Relation of Igor Bilinsky

Igor Bilinsky Owned Company Details

What does Oncternal Therapeutics Inc do?

Who are the key executives at Oncternal Therapeutics Inc?

Igor Bilinsky is the Chief Business Officer of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .

Oncternal Therapeutics Inc (ONCT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oncternal Therapeutics Inc (ONCT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oncternal Therapeutics Inc Insider Transactions

No Available Data

What does Armata Pharmaceuticals Inc do?

Who are the key executives at Armata Pharmaceuticals Inc?

Igor Bilinsky is the Chief Operating Officer of Armata Pharmaceuticals Inc. Other key executives at Armata Pharmaceuticals Inc include SVP & Finance & and PFO David Duane House , Chief Business Officer Pierre Kyme , and Corporate Controller and PFO Richard Rychlik .

Armata Pharmaceuticals Inc (ARMP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Armata Pharmaceuticals Inc (ARMP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Armata Pharmaceuticals Inc (ARMP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Armata Pharmaceuticals Inc (ARMP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Armata Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ignyta Inc do?

Who are the key executives at Ignyta Inc?

Igor Bilinsky is the GM & Immuno-Oncology/SVP Sp Ops of Ignyta Inc. Other key executives at Ignyta Inc include Chief Medical Officer Pratik S Multani , director & 10 percent owner & President & CEO & Director Jonathan E Lim , and Chief Financial Officer Jacob Chacko .

Ignyta Inc (RXDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ignyta Inc (RXDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ignyta Inc (RXDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ignyta Inc (RXDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ignyta Inc Insider Transactions

No Available Data

What does Fresh Tracks Therapeutics Inc do?

Who are the key executives at Fresh Tracks Therapeutics Inc?

Igor Bilinsky is the Senior VP & Corporate Dev't of Fresh Tracks Therapeutics Inc. Other key executives at Fresh Tracks Therapeutics Inc include Chief Medical Officer Monica E. Luchi , director & CHAIRMAN OF THE BOARD Reginald L Hardy , and General Counsel and CCO David R. Mcavoy .

Fresh Tracks Therapeutics Inc (FRTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Fresh Tracks Therapeutics Inc (FRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Fresh Tracks Therapeutics Inc (FRTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Fresh Tracks Therapeutics Inc (FRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fresh Tracks Therapeutics Inc Insider Transactions

No Available Data

What does Iovance Biotherapeutics Inc do?

Who are the key executives at Iovance Biotherapeutics Inc?

Igor Bilinsky is the Chief Operating Officer of Iovance Biotherapeutics Inc. Other key executives at Iovance Biotherapeutics Inc include Chief Financial Officer Roche Corleen M. , SVP & Finance (Int. PFO & PAO) Matthew W. Rosinack , and General Counsel Frederick G Vogt .

Iovance Biotherapeutics Inc (IOVA) Insider Trades Summary

Over the past 18 months, Igor Bilinsky made no insider transaction in Iovance Biotherapeutics Inc (IOVA). Other recent insider transactions involving Iovance Biotherapeutics Inc (IOVA) include a net purchase of 30,000 shares made by Daniel Gordon Kirby , a net purchase of 25,000 shares made by Frederick G Vogt , and a net purchase of 5,600 shares made by Raj K. Puri .

In summary, during the past 3 months, insiders sold 0 shares of Iovance Biotherapeutics Inc (IOVA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iovance Biotherapeutics Inc (IOVA) were sold and 60,600 shares were bought by its insiders, resulting in a net purchase of 60,600 shares.

Iovance Biotherapeutics Inc (IOVA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Iovance Biotherapeutics Inc Insider Transactions

No Available Data

Igor Bilinsky Mailing Address

Above is the net worth, insider trading, and ownership report for Igor Bilinsky. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Igor Bilinsky's mailing address is: San Diego Ca 92121.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.